Undruggable Leaders Virtual Forum

Undruggable Leaders Virtual Forum

September 22 - 23 | EDT Timezone

Unlocking the Previously “Undruggable”

 

In response to Covid-19, The Undruggable Leaders Forum will be taking place virtually

Registration Agenda

The Undruggable Leaders Forum is Going Virtual

Working with the leading lights of the field, we are providing even more high-quality learning and networking opportunities than before, but this time, through a truly interactive virtual experience.

With the recent impact on drug R&D, it is now more crucial than ever to discover and advance previously “undruggable” targets into the clinic and beyond.

The Undruggable Leaders Forum is Going Virtual
Your Virtual Experience
What does the Virtual Platform Offer?

Through this virtual platform comes the opportunity to personalize your experience at The Undruggable Leaders Forum. Seamlessly switch between sessions, hop in and out of meetings, connect with more key players in the industry and more are all possible depending upon your goals – and with no rushing around!

How will I Network with my Fellow Attendees?

By going virtual, you will be able to see every audience member and instantly message them. Couple this with the fact that The Forum is bringing together the movers-and-shakers from pharma, biotech and the leading academics, you will be able to meet more of these senior decision-makers before and during the event.

How can I Have Crucial Partnership Discussions?

The virtual platform enables you to spend your time more efficiently. Through the ability to book meetings, dedicated areas for 1-2-1 discussions, and built-in formats for those all important “hallway conversations”, the opportunity to meet your future partners and collaborators remains central to the event.

How will the Agenda Change?

With a new platform comes new learning opportunities. Through virtual roundtables, open discussions on dedicated topics, more time for networking and more, The Undruggable Leaders Forum will enable you to actively or passively participate through an agenda purposely-built for being virtual.

What’s the Focus of the Event?

The Undruggable Leaders Forum is “Pan-Undruggable”, focusing on the leading candidates such as RNA, KRAS, targeting protein degradation and more. Deep-dive presentations, strategic panels and dedicated roundtables will unpick the leading scientific and commercial challenges facing this industry.

What Else is on Offer?

You will have exclusive access to content and opportunities, pre and post event. Before the event officially starts, you will be able to enter the virtual platform and start connecting with your fellow attendees. After the event, you will have access to on-demand presentations, session write-ups and other resources for six months.

Speaker Faculty

Sandra Glucksmann
Sandra Glucksmann
President & CEO
Cedilla Therapeutics
Sandra Glucksmann
President & CEO
Cedilla Therapeutics

Sandra Glucksmann is a veteran biopharma executive and experienced scientist who most recently served as founder and chief operating officer of the gene editing company Editas Medicine, Inc. She previously served as senior vice president of research and development at Cerulean Pharma, which she also joined at its founding. Sandra was a founding scientist at Millennium Pharmaceuticals, where she spent 13 years, taking on a series of senior roles on the science team before moving into an executive position with responsibility for strategic program management and operations. Sandra serves on the boards of directors of gene therapy company REGENXBIO, Women in the Enterprise of Science and Technology and Scenic Biotech. Sandra holds a Ph.D. with honors in molecular genetics and cell biology from the University of Chicago. She was a post doctoral fellow at MIT.

Josh Mandel-Brehm
Josh Mandel-Brehm
CEO
CAMP4 Therapeutics
Josh Mandel-Brehm
CEO
CAMP4 Therapeutics

Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners.

Prior to his roles with CAMP4 and Polaris, Mr. Mandel-Brehm held key business development and operations leadership roles at leading biotech companies. Most recently he served as Senior Director in the Business Development and Mergers & Acquisitions group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen’s non-malignant hematology franchise and overseeing seminal investments to enter the ophthalmology field. Mr. Mandel-Brehm also played an integral role advancing Biogen’s gene therapy strategy, executing a series of external collaborations including the company’s partnership with the University of Pennsylvania. During his time at Biogen, he also served as Director, Strategy and Operations for Rare Diseases. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company’s rare disease business unit.

Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Lawrence Hamann
Lawrence Hamann
Corporate Vice President, Chemistry
Celgene
Lawrence Hamann
Corporate Vice President, Chemistry
Celgene

Larry Hamann is currently Vice President and Global Head of Chemistry at Celgene, with responsibility for Medicinal and Computational Chemistry, Biochemistry, Structural and Chemical Biology and Screening. He has over 25 years of drug discovery experience and has led or overseen teams responsible for more than 14 clinical stage compounds. At Celgene, his teams have advanced a number of molecules into development for hematologic malignancies and autoimmune diseases.

Prior to Celgene, Larry was Executive Director, Global Discovery Chemistry at Novartis, working to progress drug discovery programs.Previously, Larry was at Bristol-Myers Squibb, where he led drug discovery teams in metabolic and musculoskeletal disease, and virology. Larry began his career at Ligand Pharmaceuticals, focusing on nuclear receptor based therapeutics. Larry is co-inventor on > 70 patents and co-author on > 75 scientific publications, and serves on the NIH Study Section for Synthetic and Biological Chemistry.

In August of 2017, Larry was awarded the American Chemical Society’s Heroes of Chemistry Award for contributions to the discovery of the combination of the pioneering hepatitis C virus (HCV) NS5A inhibitor, Daklinza® (daclatasvir), and the acylsulfonamide-containing HCV NS3 protease inhibitor, Sunvepra™ (asunaprevir), which together demonstrated for the first time that HCV infection could be cured with only orally administered direct-acting antiviral agents. Larry holds a BS in Chemistry from the University of Detroit and a PhD in Organic Chemistry from the University of Michigan.

Adrian Gill
Adrian Gill
Senior Vice President, Chemistry
Revolution Medicines
Adrian Gill
Senior Vice President, Chemistry
Revolution Medicines

Adrian aspires to not only be a great medicinal chemistry leader, but a leader of great medicinal chemists. Adrian has over 23 years of drug discovery and development experience in senior roles across a diverse range of disease areas in both large pharma and biotech environments, having worked previously for Roche, Astex Therapeutics and AstraZeneca, where he was the head of medicinal chemistry for the CVMD iMed in Molndal, Sweden.

During his career to date, Adrian has been heavily involved in the identification of multiple clinical candidates across a variety of disease areas including RMC-4630, Revolution Medicines first development candidate selectively targeting SHP2 and more recently RMC-5552 which selectively targets mTORC1. Adrian was also a core member of the cell cycle kinase alliance between Astex and Novartis that ultimately led to the discovery of a dual kinase inhibitor approved by the FDA in combination treatment of HR+/HER2- advanced breast cancer. In addition, Adrian has authored over 20 publications in peer-reviewed journals, is a named inventor on over 40 issued and pending small molecule patent applications and has given multiple invited presentations at national and international conferences. Adrian received his Ph.D. in organic chemistry from the University of Sussex, U.K., where he focused on synthetic methodology towards the total synthesis of rapamycin, and has a bachelor’s degree in applied chemistry from the University of Salford, U.K.  Adrian is a member of the Royal Society of Chemistry, the American Chemical Society and an invited member of the AACR Chemistry in Cancer Research (CICR) Steering Committee.

Robert Konrat
Robert Konrat
Professor of Biomolecular Structural Chemistry
University of Vienna
Robert Konrat
Professor of Biomolecular Structural Chemistry
University of Vienna
Jennifer Petter
Jennifer Petter
Founder and Chief Scientific Officer
Arrakis Therapeutics
Jennifer Petter
Founder and Chief Scientific Officer
Arrakis Therapeutics

Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. Previously, Jennifer was Vice President of Drug Discovery at Avila Therapeutics and, upon the acquisition of Avila by Celgene in 2012, she became Celgene’s Vice President of Chemistry, a position she held until leaving to found Arrakis in 2015. Prior to Avila, Jennifer served as Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen and as Section Head in Oncology Chemistry at Sandoz/Novartis. Prior to her career in industry, Jennifer was an Assistant Professor of Chemistry at the University of Pittsburgh. Jennifer holds an A.B. in chemistry from Dartmouth College and earned her PhD in organic chemistry at Duke University with Ned Porter. She was a post-doctoral fellow in Ron Breslow’s group at Columbia University.

Howard Stern
Howard Stern
Chief Scientific Officer
FogPharma
Howard Stern
Chief Scientific Officer
FogPharma
Shuling Guo
Shuling Guo
Vice President, Antisense Drug Discovery
Ionis Pharma
Shuling Guo
Vice President, Antisense Drug Discovery
Ionis Pharma

Dr. Shuling Guo received her Ph.D. in Molecular Cancer Biology from Duke University and had her postdoctoral training at HHMI/UCLA. At Ionis, Dr. Guo oversees drug discovery efforts in hematological, metabolic, ocular, pulmonary and renal disease areas as well as research efforts in noncoding RNA field. She manages activities from target identification, target validation to the selection of human development candidate. In addition, she is involved in clinical development of antisense therapies. Dr. Guo led the research efforts for transthyretin (familial amyloid polyneuropathy, completed phase 3 clinical trial & under NDA), TMPRSS6 (beta-thalassemia and hereditary hemochromatosis, phase 1 clinical trial), and ENaC (cystic fibrosis, preclinical development).

Elizabeth Buck
Elizabeth Buck
Co-Founder, EVP, Discovery & Translational Sciences
Black Diamond Therapeutics
Elizabeth Buck
Co-Founder, EVP, Discovery & Translational Sciences
Black Diamond Therapeutics

Elizabeth Buck, Ph.D., was instrumental in developing Black Diamond’s MAP platform through which she made critical discoveries leading to our understanding of the properties of allosteric mutations in oncogene activation.

She has more than 15 years of experience in oncology therapeutics in biotechnology and large pharmaceutical companies. Her expertise and productivity are evidenced by more than 40 peer-reviewed publications and patents. Prior to co-founding Black Diamond and being named its Executive Vice President, Discovery and Translational Sciences, Liz was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, where she led discovery and translational research to advance a series of oncology programs to clinical development. During her tenure at OSI, she managed multidisciplinary global teams and spearheaded major academic collaborations to progress programs to investigational new drug applications.

Liz earned a Ph.D. in Cellular and Molecular Biology from New York University/Mount Sinai School of Medicine and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals. She received her undergraduate degree in Physics from the University of New Hampshire.

Cigall Kadoch
Cigall Kadoch
Scientific Founder/Assistant Professor
Foghorn Therapeutics/Dana Farber Cancer Institute
Cigall Kadoch
Scientific Founder/Assistant Professor
Foghorn Therapeutics/Dana Farber Cancer Institute

Cigall Kadoch, PhD, is an assistant professor of pediatric oncology at the Dana-Farber Cancer Institute, assistant professor of biological chemistry and molecular biology at Harvard Medical School, and Institute member and co-director of the epigenomics program at the Broad Institute of MIT and Harvard.

Cigall established her independent laboratory in 2014 at the age of 27, immediately following completion of her PhD studies in cancer biology at Stanford University. She is one of the youngest scientists ever appointed to the Harvard Medical School faculty. She has quickly become a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas.

 

In addition to receiving numerous prestigious awards and research grants to support her academic laboratory at Harvard—including the NIH Director’s New Innovator Award, the Pew Scholar Award, and the American Cancer Society Research Scholar Award—Cigall was named to the Forbes 2014 30 Under 30 list, MIT Technology Review’s 35 Innovators Under 35, Popular Science Brilliant 10 of 2016, and most recently Business Insider’s Top 30 Young Leaders in Biopharma.

 

Cigall holds a BA in molecular and cellular biology from the University of California, Berkeley, and a PhD in cancer biology from the Stanford University School of Medicine.

Chris O’Donnell
Chris O’Donnell
Executive Director & Principal
Pfizer Ventures
Chris O’Donnell
Executive Director & Principal
Pfizer Ventures

Christopher O’Donnell, PHD is Executive Director, WRD and Principal at Pfizer Ventures. Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Adapsyn, BioAtla, Kymera, Morphic, Petra, Storm Therapeutics, and Strata Oncology.

Chris brings 19 years of scientific leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams. He most recently built and led the Applied Synthesis Technologies group within R&D to help accelerate the delivery of Pfizer’s small molecule portfolio. Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 7 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates.

Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison.

Nello Mainolfi
Nello Mainolfi
Founder, President & Chief Executive Officer
Kymera Therapeutics
Nello Mainolfi
Founder, President & Chief Executive Officer
Kymera Therapeutics

Before founding Kymera Therapeutics, Nello was head of drug discovery at Raze Therapeutics where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and in most cases led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas. Notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

Angela Koehler
Angela Koehler
Scientific Founder/Associate Professor
Kronos Bio/Koch Institute for Integrative Cancer Research (MIT)
Angela Koehler
Scientific Founder/Associate Professor
Kronos Bio/Koch Institute for Integrative Cancer Research (MIT)

Angela is an Associate Professor in the Department of Biological Engineering at MIT and an intramural member of the David H. Koch Institute for Integrative Cancer Research at MIT. She is also a member of the MIT Center for Cancer Precision Medicine and an Associate Member of the Broad Institute. The Koehler Lab aims to innovate in the earliest stages of drug discovery by building chemical tools or technologies to assist in the process of target validation and by expanding the repertoire of protein targets that are considered to be druggable. Angela received her B.A. in Biochemistry and Molecular Biology from Reed College in 1997. In 2003, she received her Ph.D. in Chemistry from Harvard University in the laboratory of Professor Stuart Schreiber and became an Institute Fellow at the Broad Institute as well as Group Leader for the Harvard NCI Initiative for Chemical Genetics. She serves as Faculty Co-Director of the High-Throughput Sciences Facility at the Koch Institute and Faculty Co-Director of the MIT Biomedical Engineering Undergraduate Program. Dr. Koehler also serves on the Chemists in Cancer Research steering committee for the American Association for Cancer Research. Recent Awards include the Novartis Lectureship in Chemistry, the Ono Foundation Pharma Breakthrough Science Award, and being named a Genome Technology Young Investigator.

Garrett Rhyasen
Garrett Rhyasen
Director of Search & Evaluation, Global Business Development & Licensing, Oncology R&D
AstraZeneca
Garrett Rhyasen
Director of Search & Evaluation, Global Business Development & Licensing, Oncology R&D
AstraZeneca
Markus Haeberlein
Markus Haeberlein
Vice President, Head of Discovery
Alkermes
Markus Haeberlein
Vice President, Head of Discovery
Alkermes
Rich Hansen
Rich Hansen
Vice President, Discovery Technologies
Revolution Medicines
Rich Hansen
Vice President, Discovery Technologies
Revolution Medicines

Rich is a physical/analytical chemist who has spent his career at the boundaries of engineering and biology. Having worked in biopharma and synthetic biology on both the tools and discovery side of the business, he is passionate about bringing measurement and automation to biological sciences through application of existing methodology or development of completely new technologies.

Early in his career, Rich worked on one of the first confocal systems and algorithms adapted for use in high content screening. He has since held various positions leading automation, screening, informatics and other technology functions. Within these roles, he has continued to develop instrumentation to probe biological effects of compounds from the biochemical scale to intact organisms. Notably he developed a platform to measure human muscle function which was used in several clinical trials of a skeletal muscle activator.

Rich’s current department, discovery technologies, is focused on bringing measurement to the discovery process in the form of biophysical characterization, crystallography, and scientific computing to understand protein dynamics and allosteric networks.

Rich received his Ph.D. from the University of Utah and has a B.A. in chemistry from St. Olaf College.

Steve Bossone
Steve Bossone
Chief Intellectual Property Officer
Alnylam Pharmaceuticals
Steve Bossone
Chief Intellectual Property Officer
Alnylam Pharmaceuticals

Steven A. Bossone is Vice President-Intellectual Property at Alnylam Pharmaceuticals, Inc.

He previously was Principal at Tolerx, Inc., Scientist at Millennium Biotherapeutics, Inc., Scientist at Takeda Oncology Co., Senior Patent Attorney at EMD Serono, Inc. and Senior Patent Attorney at Shire US, Inc.

He received a doctorate from Stony Brook University and a graduate degree from Suffolk University Law School.

Nancy Wilker
Nancy Wilker
Vice President, Lead IP Counsel
FogPharma
Nancy Wilker
Vice President, Lead IP Counsel
FogPharma
Tamara Kale
Tamara Kale
Associate General Counsel, Intellectual Property
Revolution Medicines
Tamara Kale
Associate General Counsel, Intellectual Property
Revolution Medicines
Jake Olin
Jake Olin
Director, Business Development, Oncology
Pfizer
Jake Olin
Director, Business Development, Oncology
Pfizer
David Hepworth
David Hepworth
Vice President, Inflammation and Immunology Medicinal Chemistry
Pfizer
David Hepworth
Vice President, Inflammation and Immunology Medicinal Chemistry
Pfizer
Ann Boriack-Sjodin
Ann Boriack-Sjodin
Vice President, Molecular Discovery
Accent Therapeutics
Ann Boriack-Sjodin
Vice President, Molecular Discovery
Accent Therapeutics

Ann Boriack-Sjodin joined Accent in 2017 as Vice President of Molecular Discovery, bringing 20+ years of drug discovery experience to the role.  She has spent most of her industrial career using structural biology, biochemical and biophysical methods to progress drug discovery programs from early target validation through development candidate nomination in a variety of therapeutic areas.

Agenda

  • Tuesday, September 22nd
  • Wednesday, September 23rd
Tuesday, September 22nd
8:00 am
Breakfast and Networking

Enjoy your regular morning breakfast with your fellow attendees. Whether through pre-booked meetings, random interactions or in small groups, The Undruggable Leaders Virtual Forum has got you covered.

9:00 am
Chair’s Opening Remarks & Setting the Scene

Adrian Gill, Senior Vice President, Chemistry, Revolution Medicines

9:10 am
Case Study: Unlocking the “Undruggable” by Targeting Protein Degradation

Nello Mainolfi, Founder, President & Chief Executive Officer, Kymera Therapeutics

9:35 am
Keynote Panel & Interactive Q&A - Defining the “Undruggable” Landscape

With two days ahead filled with all things “undruggable”, defining the major challenges and opportunities in this space is where we start. This panel of industry experts will examine these leading challenges and opportunities and share their lessons learned so far.

  • What crucial gaps in our current scientific understanding do we need to fill to maximize the chances of clinical success?
  • What are the common challenges that bind us together as an industry?
  • What lessons are we learning from the partnerships being struck in this space?
  • What needs to happen next for approaches targeting “undruggable” targets to reach their potential?
  • What do we hope to learn by bringing this industry together?

Through the online polling system, you can pose your questions directly to the experts and vote for which questions you’d like to hear.

Robert Konrat, Professor of Biomolecular Structural Chemistry, University of Vienna

Sandra Glucksmann, President and Chief Executive Officer, Cedilla Therapeutics

Nello Mainolfi, Founder, President & Chief Executive Officer, Kymera Therapeutics

10:35 am
Morning Refreshments & Networking

Grab your coffee or tea and virtually meet up with folks from across the audience, whether it’s for a pre-booked meeting, casual chat or anything in-between, the choice is yours.

Best in Undruggable Tech

11:10 am
Case Study - Leading the Development of RNA-Targeted Therapeutics: Lessons from Success
  • Hear about Ionis Pharmaceuticals’ antisense technology platform has birthed more than 40 first-in-class/best-in-class medicines treating cancer, cardiovascular, neurological, infectious and pulmonary diseases with the majority in Phase II/III
  • A look at how Ionis have worked to optimise their antisense technology, which overcomes common undruggable problems, such as routes of delivery, tissue targeting, and frequency and strength of dosages
  • Lessons learned from creating the world’s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis

Shuling Guo, Vice President, Antisense Drug Discovery, Ionis Pharma

11:40 am
Case Study - Presentation by Accent Therapeutics

Ann Boriack-Sjodin, Vice President, Molecular Discovery, Accent Therapeutics

12:10 am
Case Study - Targeting Undrugged Oncogenic Mutations Across Tumor Types
  • Hear how Black Diamond Therapeutics use their Mutation-Allostery-Pharmacology, or MAP, platform to target undrugged driver mutations in genetically defined cancers
  • Discussion will include how the MAP platform uses genetic and proteomic features to rank mutations found from population-level genetic sequencing for potential oncogenicity, and how these mutations are then grouped into mutation subsets using cell and tumour models
  • A look at how single small molecule kinase inhibitors are then designed for each subset, and their current preclinical pipeline targeting EGFR and HER2 mutants

Elizabeth Buck, Co-Founder, EVP, Discovery & Translational Sciences, Black Diamond Therapeutics

12:10 pm
Lunch and Networking

At last, an actual meal of your choice at a conference!  Enjoy your lunch whilst connecting with old friends or new folks you have met from your interactions so far.

2:00 pm
Case Study - Harnessing The Chromatin Regulatory System for Gene Expression
  • A look at how the chromatin regulatory system directs which genes our cells express, and how by manipulating this system genes can be turned “on” and off”
  • Hear how this novel approach compares to the more common gene editing approach
  • Hear how Foghorn have developed their Gene Traffic Control™  Product Platform to advance over preclinical 10 programs targeting diseases with genetically determined dependencies in the chromatin regulatory system

Cigall Kadoch, Scientific Founder/Assistant Professor, Foghorn Therapeutics/Dana Farber Cancer Institute

2:30 pm
Case Study - The Potential for CPMPs to Overcome the Limitations of Traditional Drugs
  • Combining broad target coverage with cell-penetrating ability, raising the prospect of universal druggability
  • Discussion of why alpha helical structure is a beneficial feature of CPMPs
  • Overview of the FogPharma platform for scalable, rapid discovery of Helicon™ Peptides
  • Helicon™ peptide discovery case study

Howard Stern, Chief Scientific Officer, FogPharma

Large Pharma & The Undruggable

3:00 pm
Presentation - Investing into the Undruggable
  • An overview of Pfizer Venture’s investment strategy
  • Focus on the undruggable landscape and why certain companies were committed to
  • Open discussion with the audience on the investment opportunities undruggable work is presenting

Chris O’Donnell, Executive Director & Principal, Pfizer Ventures

3:30 pm
Afternoon Refreshments & Networking

Catch-up with colleagues, pre-booked 1-2-1 meetings, making new connections, all are on the table.

4:30 pm
Panel Discussion and Interactive Q&A - Partnering with Pharma: Building Relationships to Unlock the Undruggable
  • In general, how do pharmaceutical companies view the undruggable industry?
  • How is risk assessed, and when is the right time in the maturation of a field to get involved?
  • Pros and cons of in-house development vs strategic collaborations?
  • What lessons are being learned from partnerships in this space?
  • What are pharma looking to identify when partnering with biotechs targeting the “undruggable?

Through the online polling system, you can pose your questions directly to the experts and vote for which questions you’d like to hear.

Jake Olin, Director, Business Development, Oncology, Pfizer

Garrett Rhyasen, Director of Search & Evaluation, Global Business Development & Licensing, Oncology R&D, AstraZeneca

Markus Haeberlein, Vice President, Head of Discovery, Alkermes

5:30 pm
Virtual Drinks Reception

Grab a glass of wine, beer or whichever drink you choose as you catch-up with old friends and make new connections, either 1-2-1 or in groups. Just because we are virtually meeting, doesn’t mean we can’t enjoy a one or two (or more) drinks together!

?:?? pm
“Close of Day 1”

We say “Close of Day 1” but it’s not really the end of the day as the conference platform will remain open so that you can keep the interactions rolling.

Download Full Agenda
Wednesday, September 23rd
8:00 am
Breakfast and Networking

Have your Wednesday morning breakfast whilst reconnecting with your new connections from the Forum so far.

9:00 am
Chair’s Opening Remarks

Adrian Gill, Senior Vice President, Chemistry, Revolution Medicines

The Next Set of Targets

9:05 am
Case Study - Modulating Protein Expression Through RNA-Targeted Small Molecules (rSMs)
  • Hear how rSMs can increase or decrease protein expression through disrupting processing, transport, stability or translation of encoding RNAs
  • A look at Arrakis’ proprietary rSM platform, which utilises their exclusive technologies TRYST, MARS and PEARL-Seq to identify rSMs on an industrial scale
  • Discussion will focus on how this approach has potential to address the entire human transcriptome, with opportunity in treating a multitude of diseases including cancer

Jennifer Petter, Founder and Chief Scientific Officer, Arrakis Therapeutics

9:35 am
Case Study - Small Molecule Microarray Technology and Transcription Factor Modulators
  • Hear about Kronos Bio’s high-throughput small molecule microarray platform can probe a target’s entire interactome, identifying binding proteins, or proteins that disrupt protein-protein complexes or affect neighbour proteins
  • Discussion will look at how Kronos is using this platform to identify transcription factor modulators and their current two preclinical programs resulting from this
  • A look at the opportunity available when targeting historically undruggable transcription factors, the inherent challenges and how Kronos has worked to overcome these

Angela Koehler, Scientific Founder/Associate Professor, Kronos Bio/Koch Institute for Integrative Cancer Research (MIT)

10:05 am
Morning Refreshments and Networking

Share a tea or coffee (virtually) with folks from across the industry.

10:35 am
Case Study - Translating Frontier Cancer Targets
  • Overview of Revolution Medicines differentiated innovation engine to drug a diverse range of frontier cancer targets, including allosteric modulation of SHP2 phosphatase and the identification of RMC-4630
  • Proprietary tri-complex technology approach to targeting oncogenic RAS(ON) mutants
  • Discovery of novel bi-steric compounds with dual modes of action to selectively target mTORC1 (identification of RMC-5552)

Rich Hansen, Vice President, Discovery Technologies, Revolution Medicines

11:05 am
Case Study - Mapping the Genome and the Signalome: CAMP4 Therapeutics
  • Hear about how CAMP4 are providing new insights in multiple therapeutic areas including the brain and liver diseases through their Gene Circuitry Platform™
  • Discussion will focus on how this platform, along with next-generation sequencing and machine learning is used to generate Gene Circuitry Maps™ which can identify pathways and druggable targets for any gene of interest
  • Hear how this technology is systematizing target discovery and revolutionising drug development

Josh Mandel-Brehm, Chief Executive Officer, CAMP4 Therapeutics

Strategies in Undruggability

11:35 am
Strategically Focused Panel & Interactive Q&A - Protecting Innovation when Drugging the Undruggable
  • Defining an appropriate IP strategy for multiple undruggable approaches, including patents and trademarks
  • How to avoid common mistakes related to IP strategies
  • How to align IP strategies and partnership strategies
  • Can we learn anything regarding IP from other industries?
  • What are the key points to remember when protecting innovation in this industry?

Through the online polling system, you can pose your questions directly to the experts and vote for which questions you’d like to hear.

Steve Bossone, Chief Intellectual Property Officer, Alnylam Pharmaceuticals

Nancy Wilker, Vice President, Lead IP Counsel, FogPharma

Tamara Kale, Associate General Counsel, Intellectual Property, Revolution Medicines

12:35 pm
Lunch and Networking

Enjoy another lunch of your choosing as you make those final connections.

2:00 pm
Strategically Focused Panel & Interactive Q&A - What's The Next Horizon in Undruggability?
  • Which targets have the potential to become ‘the next RAS’?
  • Which approaches or technologies have the best opportunity or will have the greatest impact?
  • Taking it into the clinic: When will we see more clinical trials and proof-of-concept studies coming to fruition?
  • Do we expect to see more pharma-biotech partnerships being established in the near future?
  • What can we expect to see progress within the next few years?

Through the online polling system, you can pose your questions directly to the experts and vote for which questions you’d like to hear.

Lawrence Hamann, Corporate Vice President, Chemistry, Celgene

Josh Mandel-Brehm, Chief Executive Officer, CAMP4 Therapeutics

David Hepworth, Vice President, Inflammation and Immunology Medicinal Chemistry, Pfizer

Jennifer Petter, Founder and Chief Scientific Officer, Arrakis Therapeutics

2:50 pm
Chair’s Summary

Adrian Gill, Vice President, Chemistry, Revolution Medicines

3:00 pm
Close of The Undruggable Leaders Forum 2020

Roll straight into the rest of your Wednesday, with no flight to catch!

Download Full Agenda

Virtual Conference Platform to be Announced Shortly

Partner with us

Like you, here at GreyGreen we are adapting our plans in response to the ‘new normal’.  As experts in curating fantastic audiences, we know that people still want to meet to learn and network with each other. The only difference is the “venue”.

As you adapt your marketing strategy, the same questions remain, how do you reach new prospects, demonstrate your capabilities and build brand awareness? With Grey Green you can be assured that our summits, either face to face or virtual, will deliver the audience you need to reach.

Connecting with your customer base has never been easier. We’ll bring our expertise to the table, advising you on how best to deliver your messaging and helping you prepare for the online experience. We use World-class software to ensure our summits are the best they can be.

Contact Us +
Partner with us

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration